MX391400B - Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato. - Google Patents

Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.

Info

Publication number
MX391400B
MX391400B MX2017006561A MX2017006561A MX391400B MX 391400 B MX391400 B MX 391400B MX 2017006561 A MX2017006561 A MX 2017006561A MX 2017006561 A MX2017006561 A MX 2017006561A MX 391400 B MX391400 B MX 391400B
Authority
MX
Mexico
Prior art keywords
dimethyl fumarate
formulations including
matrix formulations
pharmaceutical compositions
present
Prior art date
Application number
MX2017006561A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006561A (es
Inventor
Cheuk- Yui LEUNG
Peter Zawaneh
Shyam B Karki
Yiqing Lin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2017006561A publication Critical patent/MX2017006561A/es
Publication of MX391400B publication Critical patent/MX391400B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017006561A 2014-11-19 2015-11-19 Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato. MX391400B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081907P 2014-11-19 2014-11-19
PCT/US2015/061448 WO2016081671A1 (en) 2014-11-19 2015-11-19 Pharmaceutical matrix formulations comprising dimethyl fumarate

Publications (2)

Publication Number Publication Date
MX2017006561A MX2017006561A (es) 2018-02-21
MX391400B true MX391400B (es) 2025-03-21

Family

ID=54838418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006561A MX391400B (es) 2014-11-19 2015-11-19 Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.

Country Status (13)

Country Link
US (2) US20190083404A1 (https=)
EP (1) EP3220897A1 (https=)
JP (2) JP6901393B2 (https=)
KR (1) KR20170086053A (https=)
CN (2) CN113262205A (https=)
AU (2) AU2015349891B2 (https=)
CA (1) CA2967645A1 (https=)
EA (1) EA201791089A1 (https=)
HK (1) HK1244215A1 (https=)
IL (1) IL252105A0 (https=)
MA (1) MA40990A (https=)
MX (1) MX391400B (https=)
WO (1) WO2016081671A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987895A1 (en) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
KR102714380B1 (ko) 2021-06-09 2024-10-11 강원대학교산학협력단 경구 투여용 나노입자 및 이의 제조방법
WO2023036702A1 (en) 2021-09-09 2023-03-16 It Pharmagus Limited Method for the manufacturing of a solid body as an oral dosage form of a pharmaceutical or a food supplement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781058B2 (en) * 1999-08-31 2005-05-05 Grunenthal Gmbh Delayed-action form of administration containing tramadol saccharinate
EP1886665A1 (en) * 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
WO2010079222A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US20120165404A1 (en) * 2009-04-29 2012-06-28 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
EP2678305A4 (en) * 2011-02-25 2015-11-04 Univ Johns Hopkins CHALCONE DERIVATIVES AS NRF2 ACTIVATORS
US20130158077A1 (en) * 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
NZ627980A (en) * 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
AU2013305684B2 (en) * 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
AR094277A1 (es) * 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
CN105369562B (zh) * 2014-08-28 2019-12-20 青岛海尔洗衣机有限公司 一种带有防衣物褪色提醒功能的洗衣机

Also Published As

Publication number Publication date
CA2967645A1 (en) 2016-05-26
EA201791089A1 (ru) 2017-11-30
MX2017006561A (es) 2018-02-21
AU2021204247A1 (en) 2021-07-22
AU2015349891A1 (en) 2017-05-25
IL252105A0 (en) 2017-07-31
JP2017534667A (ja) 2017-11-24
US20190083404A1 (en) 2019-03-21
CN107205942A (zh) 2017-09-26
JP6901393B2 (ja) 2021-07-14
US20190175510A1 (en) 2019-06-13
AU2015349891B2 (en) 2021-04-01
EP3220897A1 (en) 2017-09-27
HK1244215A1 (zh) 2018-08-03
WO2016081671A8 (en) 2016-07-21
CN113262205A (zh) 2021-08-17
WO2016081671A1 (en) 2016-05-26
JP2021152046A (ja) 2021-09-30
MA40990A (fr) 2017-09-26
KR20170086053A (ko) 2017-07-25

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2020005446A (es) Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
PL3316867T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
MX391400B (es) Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.
DK3129057T3 (da) Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2017002229A1 (es) Inhibidores de bace1.
HUE066387T2 (hu) Polimerizált gyógyszert tartalmazó gyógyszerészeti készítmény
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas